2.3 Harm Reduction, Overdose Prevention, and Low-Threshold Engagement
Key Takeaways
- Harm reduction is a set of practices and a stance that meets people where they are, reduces the harms of drug use without requiring abstinence as a precondition for services, and is compatible with abstinence-oriented treatment rather than opposed to it.
- Naloxone reverses opioid overdose by competitively displacing opioids at the mu receptor; a 4 mg naloxone nasal spray has been available over the counter in the United States since 2023, and every client and family member should leave treatment with a kit and training.
- Naloxone does not reverse xylazine, a veterinary sedative increasingly present in the illicit opioid supply, but naloxone is still administered because opioids are usually present too; xylazine also causes severe soft-tissue wounds requiring medical referral.
- Syringe services programs are associated with people who inject drugs being substantially more likely to enter treatment and to stop injecting, and are not associated with increases in crime or drug use in the surrounding community.
- Overdose risk spikes after any period of reduced tolerance, including release from jail, discharge from residential treatment, and discontinuation of extended-release naltrexone, so tolerance-loss counseling is a required element of every discharge plan.
2.3 Harm Reduction, Overdose Prevention, and Low-Threshold Engagement
Harm reduction is both a set of specific practices and a stance toward people who use drugs. The practices are concrete: naloxone distribution, sterile syringe access, drug checking, safer-use education, wound care, low-threshold medication access. The stance is that a person's life and health have value right now, whether or not they stop using today, and that services should not be withheld as leverage to force a decision the person has not yet made.
For the addiction counselor, the critical point is that harm reduction and abstinence-oriented treatment are not competitors. A counselor can hold abstinence as a clinical goal, work actively toward it, and still make sure the client has naloxone in their pocket tonight. The alternative — withholding overdose prevention until someone commits to abstinence — is a strategy that only works on people who survive.
1. The Harm Reduction Stance in Clinical Practice
| Principle | What It Looks Like in the Session | What It Is Not |
|---|---|---|
| Meet the person where they are | Working on the goal the client actually has — reducing injection frequency, avoiding using alone — while keeping the door open to more | Agreeing that nothing needs to change |
| Any positive change counts | Documenting reduced use, safer route of administration, or reengagement with medical care as legitimate treatment progress | Abandoning measurable objectives |
| Reduce harm, not only use | Addressing overdose risk, infection, wounds, housing, and violence as clinical targets in their own right | Ignoring the substance use disorder |
| Non-coercive and non-judgmental | Continuing to serve a client who returns to use; no discharge-for-relapse policy | Failing to reassess the level of care when risk rises |
| People who use drugs lead | Involving people with lived experience in service design; respecting the client's expertise about their own use | Deferring clinical judgment on medical risk |
[!IMPORTANT] Administrative discharge for relapse is a clinical failure, not a consequence. Discharging a client from addiction treatment for exhibiting the primary symptom of the disorder being treated is now widely regarded as contraindicated. When use continues, the correct response is a reassessment of the ASAM dimensional profile and a revised treatment plan — which may well mean a more intensive level of care — not termination. See Section 6.3 on continued service and transfer criteria.
2. Opioid Overdose: Recognition and Response
Recognizing an overdose
The classic opioid overdose triad is pinpoint pupils, respiratory depression, and depressed level of consciousness. In practice, the counselor is looking for: unresponsive to sternal rub or shouting; breathing that is slow, shallow, gurgling, or absent; blue or grey lips and fingertips (cyanosis); limp body; and slow or absent pulse.
Distinguish overdose from heavy intoxication: a person who is very high but responsive to a sternal rub and breathing normally is not in an overdose. When in doubt, treat it as an overdose — naloxone given to a person who has not taken opioids causes no harm.
Naloxone
Mechanism. Naloxone is a competitive mu-opioid receptor antagonist with a higher receptor affinity than most opioid agonists. It displaces the opioid, restoring respiratory drive within two to three minutes when given intranasally or intramuscularly.
Forms. The 4 mg naloxone nasal spray has been available over the counter in the United States since 2023, which means clients and family members can buy it without a prescription. Higher-dose nasal formulations, intramuscular and subcutaneous injection (0.4 to 2 mg), and a nalmefene nasal spray are also available. Many states also have standing orders and free distribution through health departments and syringe services programs.
The half-life problem. Naloxone's duration of action is roughly 30 to 90 minutes, which is shorter than the duration of many opioids — notably methadone, and fentanyl in body compartments after heavy exposure. A person can be reversed, then re-overdose as the naloxone wears off. This is why calling 911 and staying with the person are not optional add-ons, and why repeat dosing may be required.
Post-reversal experience. Reversal precipitates acute withdrawal — nausea, vomiting, agitation, severe craving. The person may be angry at being "wasted." Counsel families in advance: this reaction is expected, it is not ingratitude, and the person is at very high risk of using again immediately to relieve withdrawal, which is itself a re-overdose risk.
Overdose response sequence
- Check responsiveness — shout, sternal rub.
- Call 911. Most states have Good Samaritan laws providing some protection from drug-possession charges for those who call; the protections vary by state, so know yours.
- Give naloxone — one dose intranasally, repeat every two to three minutes if there is no response.
- Support breathing — rescue breaths if trained; chest compressions if there is no pulse.
- Recovery position to prevent aspiration if breathing resumes and you must step away.
- Stay until emergency services arrive; monitor for re-sedation.
3. The Contaminated Supply: Fentanyl and Xylazine
Fentanyl now dominates the illicit opioid supply in most of the United States and is also pressed into counterfeit pills sold as oxycodone, alprazolam, or stimulants. Its potency and rapid onset compress the window for intervention and make dose estimation impossible for the user. Fentanyl test strips allow a person to check a sample before use; they detect fentanyl but not quantity, and a negative strip does not make a supply safe.
Xylazine ("tranq") is a veterinary alpha-2 agonist sedative that is not an opioid and has been found widely in the illicit opioid supply. Three clinical facts matter:
- Naloxone does not reverse xylazine. Give naloxone anyway — opioids are almost always present as well, and reversing the opioid component restores respiratory drive.
- Sedation may persist after naloxone because the xylazine component is untouched. Continue rescue breathing and emergency response rather than concluding the naloxone "did not work."
- Xylazine causes severe necrotic soft-tissue wounds, often at sites distant from injection. Wound assessment and prompt medical referral belong in routine counseling contact; untreated wounds progress to amputation.
Safer-use counseling points that reduce fatality risk without requiring abstinence: never use alone (or use a virtual overdose-response hotline); stagger use with others so one person can respond; start with a smaller test dose after any break; avoid mixing opioids with alcohol or benzodiazepines; keep naloxone within arm's reach.
4. Syringe Services and Infectious Disease Prevention
Syringe services programs (SSPs) provide sterile injection equipment, safe disposal, naloxone, testing, wound care, and — critically — a relationship with a person who is not asking them to quit today. The evidence base is consistent: participation is associated with substantially higher rates of entering treatment and of stopping injection, and with reduced HIV and hepatitis C transmission, while community-level fears about increased crime or drug use have not been borne out.
For the counselor, the practical work is referral and normalization: knowing where the nearest SSP is, being able to describe what happens there, and not treating a client's SSP participation as ambivalence about recovery. Infection control, HIV and HCV screening, and universal precautions are covered in Section 5.1.
5. The Tolerance-Loss Windows
The most predictable overdose deaths in addiction treatment occur when tolerance has fallen and the person returns to a previously routine dose. Every one of these transitions requires explicit counseling and a naloxone kit:
| Window | Why Risk Spikes | Required Counselor Action |
|---|---|---|
| Release from jail or prison | Weeks or months of enforced abstinence with no tolerance | Naloxone at release, same-week appointment, MOUD continuity arranged before release |
| Discharge from residential or withdrawal management | Tolerance lost during the stay; discharge is a high-risk day | Naloxone in hand at discharge, warm handoff to the next level of care, explicit "your old dose can kill you" conversation |
| Discontinuing extended-release naltrexone | Receptor upregulation and lost tolerance while blocked | Plan the transition, discuss the elevated risk, offer alternative MOUD |
| After any period of reduced use | Hospitalization, illness, a period of abstinence between episodes | Repeat tolerance-loss counseling every time |
| Return to use after a lapse | Person often uses their pre-treatment amount | Include the tolerance-loss script in every relapse prevention plan (Section 8.2) |
[!IMPORTANT] The single sentence to say out loud. "If you use again after this, your tolerance is not what it was — the amount that used to be normal for you can kill you now. Use less, don't use alone, and keep this naloxone where someone can reach it." Document that you said it.
A counselor responds to an apparent overdose in the agency parking lot. The person is unresponsive with shallow, gurgling breathing. The counselor calls 911 and administers 4 mg intranasal naloxone. Breathing improves and the person becomes rousable but remains heavily sedated and does not fully wake up. What is the most likely explanation and the correct next action?
A client completing a 30-day residential program tells the counselor at the discharge session, "I'm done, I don't need to talk about using anymore." The counselor nevertheless provides a naloxone kit, trains the client's partner in its use, and documents a conversation about reduced tolerance. Which statement best describes this practice?
Which statement about syringe services programs is consistent with the public health evidence base that counselors should be able to convey to clients, families, and community stakeholders?